We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BridgeBio Pharma (BBIO) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
BridgeBio Pharma (BBIO - Free Report) closed the most recent trading day at $10.02, moving +0.1% from the previous trading session. The stock outpaced the S&P 500's daily loss of 2.77%. Elsewhere, the Dow lost 2.82%, while the tech-heavy Nasdaq lost 0.83%.
Coming into today, shares of the rare disease drug developer had lost 6.88% in the past month. In that same time, the Medical sector lost 0.16%, while the S&P 500 lost 1.35%.
Wall Street will be looking for positivity from BridgeBio Pharma as it approaches its next earnings report date. The company is expected to report EPS of -$1.13, up 4.24% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.73 million, up 1796.74% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$3.95 per share and revenue of $75.02 million, which would represent changes of -1.28% and +7.61%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BridgeBio Pharma. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BridgeBio Pharma is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 178, which puts it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BridgeBio Pharma (BBIO) Gains As Market Dips: What You Should Know
BridgeBio Pharma (BBIO - Free Report) closed the most recent trading day at $10.02, moving +0.1% from the previous trading session. The stock outpaced the S&P 500's daily loss of 2.77%. Elsewhere, the Dow lost 2.82%, while the tech-heavy Nasdaq lost 0.83%.
Coming into today, shares of the rare disease drug developer had lost 6.88% in the past month. In that same time, the Medical sector lost 0.16%, while the S&P 500 lost 1.35%.
Wall Street will be looking for positivity from BridgeBio Pharma as it approaches its next earnings report date. The company is expected to report EPS of -$1.13, up 4.24% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.73 million, up 1796.74% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$3.95 per share and revenue of $75.02 million, which would represent changes of -1.28% and +7.61%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BridgeBio Pharma. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BridgeBio Pharma is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 178, which puts it in the bottom 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.